<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00921258</url>
  </required_header>
  <id_info>
    <org_study_id>0700043</org_study_id>
    <secondary_id>2007-A00871-52</secondary_id>
    <nct_id>NCT00921258</nct_id>
  </id_info>
  <brief_title>Active Control of Prostatic Cancer With Criteria of Latence</brief_title>
  <acronym>SURACAP</acronym>
  <official_title>Active Control of Prostatic Cancer With Criteria of Latence. Impact on Specific 10 Years Survival.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinique Mutualiste Chirurgicale de la Loire</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinique Mutualiste Chirurgicale de la Loire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study concern a prospective cohort pf patients with latent prostate cancer. We study the&#xD;
      specific survival at 10 years of patients who accept an active control.Patients inclusion are&#xD;
      realized in 2 stages:&#xD;
&#xD;
        -  patient with inclusion criteria (PSA &lt; 10 ng/ml, clinical stage T1c or T2a, Gleason &lt; or&#xD;
           = 6) are registered if they accept a second prostate biopsy in a 3 months delay&#xD;
&#xD;
        -  after analyse of second biopsy in central laboratory and confirmation of latent prostate&#xD;
           biopsy, patients are included if they accept active control Included patients will have&#xD;
           1 biopsy by years the first two years and then 1 biopsy each 2 years during 8 years.&#xD;
&#xD;
      If progression of cancer happens during the 10 years control, active control will be stopped&#xD;
      and patient will be treated by surgery and chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study concern the active control during 10 years of patient with latent prostate cancer&#xD;
      who accept not be treated immediately.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Financial problem (not enough budget to continue the study)&#xD;
  </why_stopped>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluates specific survival to 10 years</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate acceptation of 2nd biopsy to confirm latent cancer</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate global survival of patient in control</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the survival of patient with a secondary active treatment after a control period</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate delay to secondary treatment after a period control</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate survival rate without biological or clinical progression of cancer</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate quality of life</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>Patient with latent prostate cancer who agree to be controled instead of to be treated</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>prostate biopsy</intervention_name>
    <description>patient of control group will have :&#xD;
1 prostate biopsy 3 months after diagnostic biopsy&#xD;
1 prostate biopsy each year during 2 years&#xD;
1 prostate biopsy each 2 years during 8 years</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with latent prostate cancer who agree to be controlled instead of to be&#xD;
        immediately treated for this cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient with a latent prostatic cancer&#xD;
&#xD;
          -  aged less 75 years old,&#xD;
&#xD;
          -  life expectation higher than 10 years&#xD;
&#xD;
          -  Clinic statue T1c or T2a&#xD;
&#xD;
          -  with a seric PSA (prostatic specific antigen)smaller than 10ng/ml&#xD;
&#xD;
          -  more than 10 biopsy cores samples&#xD;
&#xD;
          -  patient with less than 3 cores samples with tumor and none care sample with more than&#xD;
             3mm of tumor&#xD;
&#xD;
          -  Gleason score inferior at 7&#xD;
&#xD;
          -  patient's agreement about project and a second biopsy which will include definitive&#xD;
             patient: realized 3 months after the first and having: 14 biopsy cores samples (10&#xD;
             like previously and 4 more specific: taking around the positives initials biopsies),&#xD;
             less than 3 cores samples with tumor, ,any cores samples with more than 3mm of tumor,&#xD;
             a Gleason score superior at 7.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient aged 75 years old and more&#xD;
&#xD;
          -  no patient's agreement&#xD;
&#xD;
          -  lack of understanding of plan&#xD;
&#xD;
          -  patient with guardianship&#xD;
&#xD;
          -  life expectation smaller than 10 years&#xD;
&#xD;
          -  patient with an other cancer less than 5 years&#xD;
&#xD;
          -  Local clinical statue greater than T2a&#xD;
&#xD;
          -  seric PSA higher than 10ng/ml&#xD;
&#xD;
          -  less than 10 biopsies&#xD;
&#xD;
          -  more than 2 positives biopsies during the first intervention&#xD;
&#xD;
          -  3 cores samples with more than 3mm of tumor&#xD;
&#xD;
          -  4th grade on the biopsies&#xD;
&#xD;
          -  patient's refuse to realize the second biopsies&#xD;
&#xD;
          -  patient who ask a treatment after the first medical examination&#xD;
&#xD;
          -  patient with less 4 special biopsies around the previously initial cores samples or&#xD;
             more than 2 positives biopsies or biopsies with more than 3mm of tumor or patient&#xD;
             having a 4 grade on biopsies, during the second medical examination.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas MOTTET, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Mutualiste Chirurgicale</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>R Azzouzi</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean-Louis DAVIN</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henri BENSADOUN</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SALOMON</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>René GASCHIGNARD</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RUFFION</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eric LECHEVALLIER</name>
      <address>
        <city>Marseille</city>
        <zip>13 385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P. ROSSI</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xavier REBILLARD</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RIGAUD Jérôme</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christophe AVANCES</name>
      <address>
        <city>NiMES</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRANI Jacques</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P Colloby</name>
      <address>
        <city>Pontoise</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Mutualiste Chirurgicale</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SOULIE Michel</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>June 12, 2009</study_first_submitted>
  <study_first_submitted_qc>June 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2009</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>latent prostate cancer</keyword>
  <keyword>Patient with latent prostate cancer</keyword>
  <keyword>PSA ≤ 10 ng/ml</keyword>
  <keyword>Clinical stage T1c or T2a</keyword>
  <keyword>Patient who accept just be control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

